Related Experiment Videos
I-653 resists degradation in rats.
D D Koblin1, E I Eger, B H Johnson
1Department of Anesthesia, Veterans Administration Medical Center, San Francisco, CA 94121.
Anesthesia and Analgesia
|June 1, 1988
Summary
The new anesthetic I-653 showed minimal metabolism in rats, unlike halothane, isoflurane, and methoxyflurane. This suggests I-653 may have fewer toxic properties.
Area of Science:
- Anesthesiology
- Pharmacology
- Toxicology
Background:
- Drug metabolism is crucial for anesthetic safety.
- Phenobarbital is a known inducer of drug-metabolizing enzymes.
- Assessing anesthetic metabolism helps predict potential toxicity.
Purpose of the Study:
- To compare the metabolic stability of a novel anesthetic, I-653, against established agents.
- To evaluate the impact of enzyme induction on anesthetic metabolism.
- To determine the potential toxicological profile of I-653 based on its metabolic pathway.
Main Methods:
- Rats were pretreated with phenobarbital or ethanol.
- Anesthetics (I-653, halothane, isoflurane, methoxyflurane) were administered at 1.6 MAC for 2 hours.
- Serum and urine fluoride ion and organic fluoride levels were measured.
- Control groups received phenobarbital without anesthetic exposure.
Main Results:
- I-653 showed minimal fluoride excretion and serum levels, similar to controls.
- Phenobarbital pretreatment led to significant metabolism of isoflurane, halothane, and methoxyflurane.
- Ethanol pretreatment increased I-653's organic fluoride excretion.
- Halothane and methoxyflurane caused marked increases in fluoride and organic fluoride levels.
Conclusions:
- I-653 exhibits significant metabolic stability compared to other volatile anesthetics.
- The minimal formation of fluoride and organic fluoride suggests a lower potential for toxicity.
- Enzyme induction significantly alters the metabolism of traditional anesthetics but not I-653.